<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978743</url>
  </required_header>
  <id_info>
    <org_study_id>NeuroHIV002</org_study_id>
    <nct_id>NCT01978743</nct_id>
  </id_info>
  <brief_title>Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen</brief_title>
  <official_title>Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study investigators will use a multi-modal imaging approach of MRS and fMRI to
      comprehensively assess the biological changes in the brain associated with EFV-based regimen
      (EFV/FTC/TDF), specifically alterations in the brain circuitry, function and local
      neurochemistry, and their correlation with neuropsychological function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a cohort of HIV-infected patients who are clinically stable on the commonly use regimen of
      EFV/emtricitabine (FTC)/truvada (TDF) or Atripla, investigators propose to replace the EFV
      component with an integrase inhibitor, Raltegravir (RAL), given as the RAL and FTC/TDF to
      evaluate the EFV-related neural alterations. This is a multidisciplinary study which will be
      lead by Dr. Nina Lin, in collaboration with the research teams of Dr. Alexander Lin, Director
      of the Center for Clinical Spectroscopy, and Dr. Emily Stern, Director of the Functional
      Neuroimaging Laboratory, both members of the Brigham and Women's Department of Radiology at
      Harvard Medical School, as well as Dr. Jane Epstein, a researcher in Dr. Stern's research
      group. Dr. Epstein is a staff psychiatrist at Brigham and Women's hospital with extensive
      experience and expertise in research on abnormalities of affective and motivational
      processing in the context of neuropsychiatric disorders. Investigators will utilize the
      established clinical research platform in the Infectious Disease outpatient clinical practice
      at the Brigham and Women's Hospital, where there is currently have many ongoing HIV-related
      studies and a large panel of HIV-infected patients motivated to be involved in clinically
      relevant research. Investigators propose to use advanced neuroimaging to measure biologically
      changes in the brain associated with long-term EFV use with the following specific aims:

        1. Determine changes in neurometabolites measured by MRS in the brain associated with
           long-term EFV use

        2. Assess for alterations in neural activity correlated with affective symptoms associated
           with EFV vs RAL use using fMRI, and their associations with changes in neurometabolites
           assessed by MRS, and with changes in cognition assessed by Trail Making and Digit
           Substitution Tests.

        3. Determine changes in emotion, cognition and sleep quality after switching from EFV to
           RAL, and how they correlate with subject treatment preference.

      This clinical study will extend our current understanding of EFV neurotoxicity by further
      defining the nature of these biological changes. Further elucidation of the neurobiological
      underpinnings of EFV-induced CNS toxicity will have clinical relevance in improving the
      quality of life and drug adherence of HIV-infected patients on ART, especially among older
      patients or those with baseline neuropsychiatric disorders, whom at baseline are more
      vulnerable to neurocognitive decline from long-term HIV infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS)</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Assess the levels of neuro-metabolites measured by MRS at week 0 before switching to the efavirenz-based therapy. Two areas of the brain: 1) posterior cingulate gyrus and 2) anterior cingulate will be assessed for the levels of brain creatine (Cr), gamma-aminobutyric acid (GABA) and glutathione (GLU).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neural Activation Networks Using Functional Magnetic Resonance Imaging (fMRI)</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Assess changes in neural activation correlated with affective disturbances associated with EFV vs. RAL using fMRI employing a paradigm that probes affective symptomatologies typical with EFV use; anxiety/dysphoria and affective dysregulation, and their association with changes in cognitive function. Four brain regions of interests (ROIs) are specified to show the differential frontal-limbic activation patterns in the task-evoked neural responses to the 3 linear contrasts of Pre-/Post-/ Pre-vs. Post-switch: [Negative Word vs. Neutral Word] x [No-Go Trial Block vs. Go Trial Block]: anterior Frontal Pole (aFP), posterior Cingulate Gyrus (pCG), dorsal anterior Cingulate Gyrus (daCG), Left Hippocampus (LHC). A linear mixed-effects model is utilized to examine the effect sizes of the key Regimen/Condition contrasts, with the Subject factor as the random-effect, and Age incorporated as a co-variate of no interest. A z-score is the Mean with a SD=1 and Measure of Dispersion equal to 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other Neurometabolite Changes Measured by MRS</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Use MRS to evaluate a fuller panel of known neurometabolites (in addition to the primary endpoints) to evaluate for prominent and significant changes associated with EFV use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Changes Measured by a Panel of Indexes: WAIS-R, HAMD, DASS-21, FRSBE, STAI</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Assess for changes in cognitive and affective function prior to and after switching off EFV-based regimen. Indexes used to access neurocognitive changes included:
Wechsler Adult Intelligence Scale (WAIS-R) Digital Symbol Substitution Test: sensitive to brain dmamage, dementia, age and depressive changes. Range of 0-100, the higher the score the better the person's performance
Hamilton Rating Scale for Depression (HAMD): Measure of depression. Score of 0-7 is normal, score of &gt;20 is moderate/severe depression
Depression Anxiety Stress Scale (DASS-21) the lower the score, the less severe depression, anxiety and stress. Scale range of 0-63
Frontal Systems Behavior Scale (FRSBE): Increased score indicates greater behavioral impairment associated with frontal systems, range 37.2 to 186
Spielberger state trait anxiety inventory (STAI): the higher the score the greater then anxiety level, range of 20 to 80.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipid Profile</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Measure the change in fasting lipid panel prior to and after switching off EFV-based regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Assess for changes in sleep pattern and quality prior to and after switching off EFV-based regimen through a self-administered Pittsburg Sleep Quality Index (PSQI). Measure consists of 19 items with each weighted on 0-3 scale and the sum produces a total score, which ranges from 0-21. The lower the score the healthier the sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART Regimen Preference</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Evaluate patient preference in ART regimen (Atripla, EFV/FTC/TDF versus RAL + FTC/TDF) through self-administered questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Immune Activation</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Change in markers of immune activation and inflammation associated with change to RAL (ie, sCD14, IL-6, hsCRP, D-dimer, CRP, LPS, sCD163, EndoCab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Level of EFV and Metabolites</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Correlate change in level of EFV and metabolites with neurocognitive and neuroimaging changes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>HIV</condition>
  <condition>HIV-associated Neurocognitive Disorder</condition>
  <condition>Neurotoxicity</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF). Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Raltegravir (Isentress) 400mg BID</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic HIV-infected individuals on suppressive regimen with EFV/FTC/TDF, for at least
             6 months

          2. Undetectable HIV-1 RNA virus load for at least 6 months

          3. No co-infections with active hepatitis B and C

          4. Presence of at least moderate symptoms on 2 out of 3 subcores on the DASS

          5. No known active HIV-related and non-HIV related CNS infections

          6. Estimated glomerular filtration rate (EGFR) &gt;60 ml/min

          7. Consent to switching to EVG/COBI/FTC/TDF

          8. Ages 18 - 65

        Exclusion Criteria:

          1. History of CNS opportunistic infections or active CNS infections

          2. History of severe psychiatric disorder (excluding depression and anxiety)

          3. History of chronic neurological disorders, such as epilepsy or multiple sclerosis

          4. History of or current significant substance abuse or dependence and/or heavy alcohol
             use (&gt;12 oz/wk)

          5. Any women who may be pregnant (positive urine pregnancy test or unprotected sex in 2
             weeks prior to scan) or known to be pregnant

          6. Contraindications to undergoing fMRI, including metallic implants, claustrophobia, and
             medical conditions or medications that significantly affect cerebral blood flow or
             function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <results_first_submitted>June 8, 2017</results_first_submitted>
  <results_first_submitted_qc>July 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2017</results_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University</investigator_affiliation>
    <investigator_full_name>Nina Lin, MD</investigator_full_name>
    <investigator_title>Assistant Professor in Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HIV-associated neurocognitive disorder</keyword>
  <keyword>neurotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
    <mesh_term>Neurocognitive Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir</title>
          <description>All participants are switched from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + truvada (FTC/TDF).
Raltegravir will be administered 400mg twice-a-day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir</title>
          <description>All 10 participants were switched from Atripla to twice daily Raltegravir and Truvada (FTC/TDF)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS)</title>
        <description>Assess the levels of neuro-metabolites measured by MRS at week 0 before switching to the efavirenz-based therapy. Two areas of the brain: 1) posterior cingulate gyrus and 2) anterior cingulate will be assessed for the levels of brain creatine (Cr), gamma-aminobutyric acid (GABA) and glutathione (GLU).</description>
        <time_frame>week 0 and week 8</time_frame>
        <population>The arbitrary units are expressed as the output from MRS software. While similar to concentration (mM) due to assumptions in the software, it is best expressed as arbitrary units for comparison from week 0 to week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF). Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.
Drug switch from Atripla: Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS)</title>
          <description>Assess the levels of neuro-metabolites measured by MRS at week 0 before switching to the efavirenz-based therapy. Two areas of the brain: 1) posterior cingulate gyrus and 2) anterior cingulate will be assessed for the levels of brain creatine (Cr), gamma-aminobutyric acid (GABA) and glutathione (GLU).</description>
          <population>The arbitrary units are expressed as the output from MRS software. While similar to concentration (mM) due to assumptions in the software, it is best expressed as arbitrary units for comparison from week 0 to week 8.</population>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-switch Posterior Cingulate Creatine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.38" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-switch Posterior Cingulate Creatine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.94" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-switch Posterior Cingulate Glutamate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.83" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-switch Posterior Cingulate Glutamate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.95" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-switch Posterior Cingulate GABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.27" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-switch Posterior Cingulate GABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.32" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-switch Anterior Cingulate Creatine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.86" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-switch Anterior Cingulate Creatine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.34" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-switch Anterior Cingulate Glutamate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.09" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-switch Anterior Cingulate Glutamate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.25" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-switch Anterior Cingulate GABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-switch Anterior Cingulate GABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Neural Activation Networks Using Functional Magnetic Resonance Imaging (fMRI)</title>
        <description>Assess changes in neural activation correlated with affective disturbances associated with EFV vs. RAL using fMRI employing a paradigm that probes affective symptomatologies typical with EFV use; anxiety/dysphoria and affective dysregulation, and their association with changes in cognitive function. Four brain regions of interests (ROIs) are specified to show the differential frontal-limbic activation patterns in the task-evoked neural responses to the 3 linear contrasts of Pre-/Post-/ Pre-vs. Post-switch: [Negative Word vs. Neutral Word] x [No-Go Trial Block vs. Go Trial Block]: anterior Frontal Pole (aFP), posterior Cingulate Gyrus (pCG), dorsal anterior Cingulate Gyrus (daCG), Left Hippocampus (LHC). A linear mixed-effects model is utilized to examine the effect sizes of the key Regimen/Condition contrasts, with the Subject factor as the random-effect, and Age incorporated as a co-variate of no interest. A z-score is the Mean with a SD=1 and Measure of Dispersion equal to 1.</description>
        <time_frame>week 0 and week 8</time_frame>
        <population>8 of 10 enrolled patients passed QA testing to qualify for final fMRI data analyses. The 3 linear contrasts of Pre-switch/Post-switch/Pre- vs. Post-switch: [Neg vs.Neu] x [No-Go vs. Go] are reported as z-score (standardized effect size measures with SD=1). Z-score is obtained for each subject, group Z-score is obtained via a mixed-effects model.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF). Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.
Drug switch from Atripla: Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Neural Activation Networks Using Functional Magnetic Resonance Imaging (fMRI)</title>
          <description>Assess changes in neural activation correlated with affective disturbances associated with EFV vs. RAL using fMRI employing a paradigm that probes affective symptomatologies typical with EFV use; anxiety/dysphoria and affective dysregulation, and their association with changes in cognitive function. Four brain regions of interests (ROIs) are specified to show the differential frontal-limbic activation patterns in the task-evoked neural responses to the 3 linear contrasts of Pre-/Post-/ Pre-vs. Post-switch: [Negative Word vs. Neutral Word] x [No-Go Trial Block vs. Go Trial Block]: anterior Frontal Pole (aFP), posterior Cingulate Gyrus (pCG), dorsal anterior Cingulate Gyrus (daCG), Left Hippocampus (LHC). A linear mixed-effects model is utilized to examine the effect sizes of the key Regimen/Condition contrasts, with the Subject factor as the random-effect, and Age incorporated as a co-variate of no interest. A z-score is the Mean with a SD=1 and Measure of Dispersion equal to 1.</description>
          <population>8 of 10 enrolled patients passed QA testing to qualify for final fMRI data analyses. The 3 linear contrasts of Pre-switch/Post-switch/Pre- vs. Post-switch: [Neg vs.Neu] x [No-Go vs. Go] are reported as z-score (standardized effect size measures with SD=1). Z-score is obtained for each subject, group Z-score is obtained via a mixed-effects model.</population>
          <units>z-score</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PreVsPostXNegVsNeuXNoGoVsGo: aFP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PreVsPostXNegVsNeuXNoGoVsGo: pCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PreVsPostXNegVsNeuXNoGoVsGo: daCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PreVsPostXNegVsNeuXNoGoVsGo:LHC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre: NegVsNeuXNoGoVsGo: aFP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre: NegVsNeuXNoGoVsGo:pCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre: NegVsNeuXNoGoVsGo: daCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre: NegVsNeuXNoGoVsGo: LHC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post: NegVsNeuXNoGoVsGo: aFP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post: NegVsNeuXNoGoVsGo: pCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post: NegVsNeuXNoGoVsGo: daCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post: NegVsNeuXNoGoVsGo: LHC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Neurometabolite Changes Measured by MRS</title>
        <description>Use MRS to evaluate a fuller panel of known neurometabolites (in addition to the primary endpoints) to evaluate for prominent and significant changes associated with EFV use.</description>
        <time_frame>week 0 and week 8</time_frame>
        <population>The arbitrary units are expressed as the output from MRS software. While similar to concentration (mM) due to assumptions in the software, it is best expressed as arbitrary units for comparison from week 0 to week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF). Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.
Drug switch from Atripla: Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Other Neurometabolite Changes Measured by MRS</title>
          <description>Use MRS to evaluate a fuller panel of known neurometabolites (in addition to the primary endpoints) to evaluate for prominent and significant changes associated with EFV use.</description>
          <population>The arbitrary units are expressed as the output from MRS software. While similar to concentration (mM) due to assumptions in the software, it is best expressed as arbitrary units for comparison from week 0 to week 8.</population>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-switch Posterior Cingulate Glutathione</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-switch Posterior Cingulate Glutathione</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.70" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-switch Posterior Cingulate Aspartate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-switch Posterior Cingulate Aspartate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-switch Anterior Cingulate Glutathione</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-switch Anterior Cingulate Glutathione</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-switch Anterior Cingulate Aspartate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-switch Anterior Cingulate Aspartate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Changes Measured by a Panel of Indexes: WAIS-R, HAMD, DASS-21, FRSBE, STAI</title>
        <description>Assess for changes in cognitive and affective function prior to and after switching off EFV-based regimen. Indexes used to access neurocognitive changes included:
Wechsler Adult Intelligence Scale (WAIS-R) Digital Symbol Substitution Test: sensitive to brain dmamage, dementia, age and depressive changes. Range of 0-100, the higher the score the better the person's performance
Hamilton Rating Scale for Depression (HAMD): Measure of depression. Score of 0-7 is normal, score of &gt;20 is moderate/severe depression
Depression Anxiety Stress Scale (DASS-21) the lower the score, the less severe depression, anxiety and stress. Scale range of 0-63
Frontal Systems Behavior Scale (FRSBE): Increased score indicates greater behavioral impairment associated with frontal systems, range 37.2 to 186
Spielberger state trait anxiety inventory (STAI): the higher the score the greater then anxiety level, range of 20 to 80.</description>
        <time_frame>week 0 and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF). Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.
Drug switch from Atripla: Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Changes Measured by a Panel of Indexes: WAIS-R, HAMD, DASS-21, FRSBE, STAI</title>
          <description>Assess for changes in cognitive and affective function prior to and after switching off EFV-based regimen. Indexes used to access neurocognitive changes included:
Wechsler Adult Intelligence Scale (WAIS-R) Digital Symbol Substitution Test: sensitive to brain dmamage, dementia, age and depressive changes. Range of 0-100, the higher the score the better the person's performance
Hamilton Rating Scale for Depression (HAMD): Measure of depression. Score of 0-7 is normal, score of &gt;20 is moderate/severe depression
Depression Anxiety Stress Scale (DASS-21) the lower the score, the less severe depression, anxiety and stress. Scale range of 0-63
Frontal Systems Behavior Scale (FRSBE): Increased score indicates greater behavioral impairment associated with frontal systems, range 37.2 to 186
Spielberger state trait anxiety inventory (STAI): the higher the score the greater then anxiety level, range of 20 to 80.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-switch WAIS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1" spread="12.53838551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch WAIS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5" spread="12.00231459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch FRSBE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="13.07074766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch FRSBE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="9.834180754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch HAMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="3.860051813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch HAMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.020301677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch DASS depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="9.834180754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch DASS depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="3.777124126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch STAI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="5.481281278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch STAI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="6.528569692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Lipid Profile</title>
        <description>Measure the change in fasting lipid panel prior to and after switching off EFV-based regimen.</description>
        <time_frame>week 0 and week 8</time_frame>
        <population>Change in lipid panel pre- and post-switch to RAL-based regimen</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>All 10 participants were switched from Atripla to twice daily Raltegravir and Truvada (FTC/TDF)</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Lipid Profile</title>
          <description>Measure the change in fasting lipid panel prior to and after switching off EFV-based regimen.</description>
          <population>Change in lipid panel pre- and post-switch to RAL-based regimen</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-switch total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.9" spread="37.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.7" spread="26.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" spread="13.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.8" spread="31.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.5" spread="24.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch triglyceride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.4" spread="69.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch triglyceride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.6" spread="54.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality</title>
        <description>Assess for changes in sleep pattern and quality prior to and after switching off EFV-based regimen through a self-administered Pittsburg Sleep Quality Index (PSQI). Measure consists of 19 items with each weighted on 0-3 scale and the sum produces a total score, which ranges from 0-21. The lower the score the healthier the sleep quality.</description>
        <time_frame>week 0 and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>All 10 participants were switched from Atripla to twice daily Raltegravir and Truvada (FTC/TDF)</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality</title>
          <description>Assess for changes in sleep pattern and quality prior to and after switching off EFV-based regimen through a self-administered Pittsburg Sleep Quality Index (PSQI). Measure consists of 19 items with each weighted on 0-3 scale and the sum produces a total score, which ranges from 0-21. The lower the score the healthier the sleep quality.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-switch PSQI index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch PSQI index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ART Regimen Preference</title>
        <description>Evaluate patient preference in ART regimen (Atripla, EFV/FTC/TDF versus RAL + FTC/TDF) through self-administered questionnaires.</description>
        <time_frame>week 0 and week 8</time_frame>
        <population>Each participant was asked a single self-administered question on their ART preference and asked to chose one of the 3 answers; 1. prefer to take Atripla, 2. prefer RAL-based regimen (that they received in study) or 3. no preference.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>All 10 participants were switched from Atripla to twice daily Raltegravir and Truvada (FTC/TDF)</description>
          </group>
        </group_list>
        <measure>
          <title>ART Regimen Preference</title>
          <description>Evaluate patient preference in ART regimen (Atripla, EFV/FTC/TDF versus RAL + FTC/TDF) through self-administered questionnaires.</description>
          <population>Each participant was asked a single self-administered question on their ART preference and asked to chose one of the 3 answers; 1. prefer to take Atripla, 2. prefer RAL-based regimen (that they received in study) or 3. no preference.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prefer Raltegravir-based ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prefer Atripla (EFV-based ART)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No preference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Immune Activation</title>
        <description>Change in markers of immune activation and inflammation associated with change to RAL (ie, sCD14, IL-6, hsCRP, D-dimer, CRP, LPS, sCD163, EndoCab)</description>
        <time_frame>week 0 and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>All 10 participants were switched from Atripla to twice daily Raltegravir and Truvada (FTC/TDF)</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Immune Activation</title>
          <description>Change in markers of immune activation and inflammation associated with change to RAL (ie, sCD14, IL-6, hsCRP, D-dimer, CRP, LPS, sCD163, EndoCab)</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-switch sCD14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3652333.6" spread="771769.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch sCD14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3135828.52" spread="791445.1417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.84" spread="74.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.85" spread="55.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch sCD163</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="672844" spread="281620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch sCD163</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="733536" spread="378.958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch MCP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.578" spread="34.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch MCP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.794" spread="56.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch TNFR1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="771.18" spread="145.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch TNFR1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="829.12" spread="130.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Level of EFV and Metabolites</title>
        <description>Correlate change in level of EFV and metabolites with neurocognitive and neuroimaging changes</description>
        <time_frame>week 0 and week 8</time_frame>
        <population>Level of EFV (efavirenz) in Atripla and its two known metabolites known to cause cerebral side effects, 7-hydroxy (OH) EFV and 8-OH EFV, were measured in the plasma prior to switch off Atripla and after 8 weeks of RAL-based regimen (no EFV).</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>All 10 participants were switched from Atripla to twice daily Raltegravir and Truvada (FTC/TDF)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Level of EFV and Metabolites</title>
          <description>Correlate change in level of EFV and metabolites with neurocognitive and neuroimaging changes</description>
          <population>Level of EFV (efavirenz) in Atripla and its two known metabolites known to cause cerebral side effects, 7-hydroxy (OH) EFV and 8-OH EFV, were measured in the plasma prior to switch off Atripla and after 8 weeks of RAL-based regimen (no EFV).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-switch detectable 7-OH and 8-OH EFV metablites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch detectable 7-OH and 8-OH EFVmetaboites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir</title>
          <description>All 10 participants were switched from Atripla to twice daily Raltegravir and Truvada (FTC/TDF)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nina Lin</name_or_title>
      <organization>Boston University School of Medicine</organization>
      <phone>617-414-5242</phone>
      <email>nina.lin@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

